Clinical Trial Update: Leniolisib for Immune Dysregulation in CVID [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating leniolisib for immune dysregulation in Common Variable Immunodeficiency (CVID) is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency

Drugs mentioned

• Leniolisib (leniolisib)

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: Common Variable Immunodeficiency (CVID) | Phase 2 | Status: ACTIVE_NOT_RECRUITING